IFM Investors Pty Ltd Has $30.16 Million Position in Danaher Corporation (NYSE:DHR)

IFM Investors Pty Ltd increased its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 11.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 147,142 shares of the conglomerate's stock after buying an additional 14,734 shares during the period. IFM Investors Pty Ltd's holdings in Danaher were worth $30,164,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of DHR. Norges Bank bought a new stake in Danaher during the fourth quarter valued at $2,130,740,000. GAMMA Investing LLC raised its position in shares of Danaher by 24,958.2% in the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after acquiring an additional 1,863,381 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Danaher in the 4th quarter valued at about $391,172,000. Two Sigma Advisers LP boosted its position in shares of Danaher by 4,248.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock valued at $376,347,000 after purchasing an additional 1,601,800 shares in the last quarter. Finally, Capital World Investors grew its stake in Danaher by 32.7% during the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock worth $1,460,215,000 after purchasing an additional 1,566,658 shares during the period. Institutional investors own 79.05% of the company's stock.

Danaher Stock Performance

NYSE DHR opened at $203.08 on Friday. The company has a fifty day moving average price of $195.52 and a 200-day moving average price of $207.59. The firm has a market cap of $145.33 billion, a price-to-earnings ratio of 39.43, a PEG ratio of 2.84 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. The business had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. As a group, equities research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.63%. Danaher's dividend payout ratio is presently 24.85%.

Wall Street Analyst Weigh In

DHR has been the topic of several recent analyst reports. Argus dropped their price target on Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. The Goldman Sachs Group dropped their target price on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Citigroup reissued a "buy" rating on shares of Danaher in a research note on Monday, April 7th. JPMorgan Chase & Co. decreased their price target on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a research note on Tuesday, April 22nd. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and an average target price of $248.61.

Insider Buying and Selling

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president owned 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman directly owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.